An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A

Allergan110 enrolled

Overview

This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Facial Rhytides

Interventions

botulinum toxin Type ADRUG

Previous treatment with botulinum toxin Type A for treatment of facial lines

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previously treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A preparation * Received 2 treatment cycles wtih botulinum toxin Type A (BOTOX®) prior to at least 1 treatment with botulinum toxin Type A (Xeomin®) Exclusion Criteria: * None

Locations (1)

Unnamed facility

Buenos Aires, Argentina

Outcomes

Primary Outcomes

Average Total Dose Per Treatment Period

Average total dose per treatment period was defined as total treatment dose plus total touch-up dose plus total follow-up dose.

Time frame: 24 Months

Secondary Outcomes

Inter-Injection Interval Duration of Each Treatment Period

Inter-injection interval duration of each treatment period. Duration is defined as the number of days of an injection cycle.

Time frame: 24 Months

Percent of Subjects Reporting Satisfaction With Treatment Effects

Percent of subjects reporting satisfaction with treatment effects per chart notes.

Time frame: 24 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.